Nanopath
Nanopath is seeking a co-op to support and manage assay development tasks within a fast-paced biotech startup environment. The role involves collaborating with scientists and engineers to drive product development while participating in critical team discussions and presentations. This full-time, onsite position offers an opportunity to gain hands-on experience in molecular biology, cell culture, and interdisciplinary medtech development.
Headquarters
Cambridge, Massachusetts, United States
Company Size
11-50 employees
Founded
2019
Nanopath is a diagnostics company focused on women's health that develops advanced molecular testing technologies. The company says it has achieved deep technological breakthroughs—using nano‑enabled approaches—that have the potential to change the molecular diagnostic paradigm. Nanopath aims to translate those innovations into diagnostic platforms and assays that improve sensitivity, speed, and clinical decision‑making in women’s healthcare.
Nanopath Granted FDA Breakthrough Device Designation for Its Molecular Diagnostic Platform for Urinary Tract Infections
Nov 18, 2025
FDA Grants Breakthrough Device Designation to Nanopath’s UTI Diagnostic Platform
Nov 18, 2025
Nanopath Expands Leadership Team
Nov 12, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Nanopath .
Nanopath didn’t post a salary, so this is our estimate from similar listings.
18% above the average for this role
FDA clearances: Dexcom, GE HealthCare, Zimmer Biomet, BrainsWay
Nov 20, 2025